Barrett Esophagus and Intramucosal Esophageal Adenocarcinoma

Hematol Oncol Clin North Am. 2017 Jun;31(3):409-426. doi: 10.1016/j.hoc.2017.01.003. Epub 2017 Mar 22.


Barrett esophagus (BE) is a precursor lesion for esophageal adenocarcinoma (EAC). Developments in imaging and molecular markers, and endoscopic eradication therapy, are available to curb the increase of EAC. Endoscopic surveillance is recommended, despite lack of data. The cancer risk gets progressively downgraded, raising questions about the understanding of risk factors and molecular biology involved. Recent data point to at least 2 carcinogenic pathways operating in EAC. The use of p53 overexpression and high-risk human papillomavirus may represent the best chance to detect progressors. Genome-wide technology may provide molecular signatures to aid diagnosis and risk stratification in BE.

Keywords: Barrett esophagus; Esophageal adenocarcinoma; Human papillomavirus; Screening; Surveillance.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma* / genetics
  • Adenocarcinoma* / metabolism
  • Adenocarcinoma* / pathology
  • Adenocarcinoma* / surgery
  • Animals
  • Barrett Esophagus* / genetics
  • Barrett Esophagus* / metabolism
  • Barrett Esophagus* / pathology
  • Barrett Esophagus* / surgery
  • Biomarkers, Tumor* / genetics
  • Biomarkers, Tumor* / metabolism
  • Endoscopy*
  • Esophageal Neoplasms* / genetics
  • Esophageal Neoplasms* / metabolism
  • Esophageal Neoplasms* / pathology
  • Esophageal Neoplasms* / surgery
  • Gene Expression Regulation, Neoplastic
  • Genome-Wide Association Study
  • Humans
  • Risk Assessment
  • Tumor Suppressor Protein p53* / genetics
  • Tumor Suppressor Protein p53* / metabolism


  • Biomarkers, Tumor
  • TP53 protein, human
  • Tumor Suppressor Protein p53